You just read:

Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200

News provided by

Protagonist Therapeutics, Inc.

May 04, 2017, 17:23 ET